12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pradaxa dabigatran etexilate: Phase III data

The double-blind, international Phase III RE-MEDY trial in 2,856 VTE patients who had received at least 3 months of therapy with Pradaxa or an approved anticoagulant and were considered to be at an increased risk for recurrent VTE showed that extended treatment for 6-36 months with twice-daily 150 mg Pradaxa met the primary endpoint of non-inferiority to warfarin in preventing recurrent or fatal...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >